Is China Pharma Stock a Good Investment?
China Pharma Investment Advice | CPHI |
- Examine China Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research China Pharma's leadership team and their track record. Good management can help China Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact China Pharma's business and its evolving consumer preferences.
- Compare China Pharma's performance and market position to its competitors. Analyze how China Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if China Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about China Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in China Pharma Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if China Pharma Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine China Pharma Stock
Researching China Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. China Pharma Holdings recorded a loss per share of 0.69. The entity had not issued any dividends in recent years. The firm had 1:5 split on the 6th of March 2024.
To determine if China Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding China Pharma's research are outlined below:
| China Pharma is way too risky over 90 days horizon | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma appears to be risky and price may revert if volatility continues | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 51.0% of China Pharma shares are held by company insiders | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Wednesdays After-Market Session - Benzinga |
China Pharma Quarterly Cost Of Revenue |
|
China Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in China Pharma Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to China Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
China Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.69 M.Market Cap |
|
China Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.47) | (0.45) |
Determining China Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if China Pharma is a good buy. For example, gross profit margin measures China Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of China Pharma's profitability and make more informed investment decisions.
Evaluate China Pharma's management efficiency
China Pharma Holdings has return on total asset (ROA) of (0.1754) % which means that it has lost $0.1754 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7489) %, meaning that it created substantial loss on money invested by shareholders. China Pharma's management efficiency ratios could be used to measure how well China Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.23. The China Pharma's current Return On Capital Employed is estimated to increase to -0.31. As of now, China Pharma's Intangible Assets are increasing as compared to previous years. The China Pharma's current Intangibles To Total Assets is estimated to increase to 0.21, while Total Assets are projected to decrease to under 18 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.53 | 2.41 | |
| Tangible Book Value Per Share | 1.29 | 1.23 | |
| Enterprise Value Over EBITDA | 716.67 | 752.50 | |
| Price Book Value Ratio | 0.25 | 0.26 | |
| Enterprise Value Multiple | 716.67 | 752.50 | |
| Price Fair Value | 0.25 | 0.26 | |
| Enterprise Value | 6 M | 5.7 M |
Examining the leadership quality of China Pharma Holdings offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 0.711 |
Basic technical analysis of China Stock
As of the 25th of March, China Pharma shows the Downside Deviation of 9.81, mean deviation of 6.9, and Risk Adjusted Performance of 0.0916. China Pharma Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.China Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific China Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on China Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases China Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Liu Tao (chengdu) over six months ago Disposition of tradable shares by Liu Tao of China Pharma subject to Rule 16b-3 | ||
Liu Tao Chengdu over a year ago China Pharma exotic insider transaction detected | ||
Zhilin Li over a year ago Acquisition by Zhilin Li of 13757063 shares of China Pharma subject to Rule 16b-3 | ||
Deng Ke over a year ago China Pharma exotic insider transaction detected |
China Pharma's Outstanding Corporate Bonds
China Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. China Pharma Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most China bonds can be classified according to their maturity, which is the date when China Pharma Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand China Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing China Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0916 | |||
| Market Risk Adjusted Performance | 0.9047 | |||
| Mean Deviation | 6.9 | |||
| Semi Deviation | 6.95 | |||
| Downside Deviation | 9.81 | |||
| Coefficient Of Variation | 1093.4 | |||
| Standard Deviation | 9.58 | |||
| Variance | 91.72 | |||
| Information Ratio | 0.0942 | |||
| Jensen Alpha | 0.9012 | |||
| Total Risk Alpha | 1.25 | |||
| Sortino Ratio | 0.092 | |||
| Treynor Ratio | 0.8947 | |||
| Maximum Drawdown | 45.32 | |||
| Value At Risk | (14.29) | |||
| Potential Upside | 20.83 | |||
| Downside Variance | 96.23 | |||
| Semi Variance | 48.34 | |||
| Expected Short fall | (11.23) | |||
| Skewness | 0.5218 | |||
| Kurtosis | 0.6413 |
| Risk Adjusted Performance | 0.0916 | |||
| Market Risk Adjusted Performance | 0.9047 | |||
| Mean Deviation | 6.9 | |||
| Semi Deviation | 6.95 | |||
| Downside Deviation | 9.81 | |||
| Coefficient Of Variation | 1093.4 | |||
| Standard Deviation | 9.58 | |||
| Variance | 91.72 | |||
| Information Ratio | 0.0942 | |||
| Jensen Alpha | 0.9012 | |||
| Total Risk Alpha | 1.25 | |||
| Sortino Ratio | 0.092 | |||
| Treynor Ratio | 0.8947 | |||
| Maximum Drawdown | 45.32 | |||
| Value At Risk | (14.29) | |||
| Potential Upside | 20.83 | |||
| Downside Variance | 96.23 | |||
| Semi Variance | 48.34 | |||
| Expected Short fall | (11.23) | |||
| Skewness | 0.5218 | |||
| Kurtosis | 0.6413 |
Consider China Pharma's intraday indicators
China Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of China Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
China Pharma time-series forecasting models is one of many China Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary China Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
China Stock media impact
Far too much social signal, news, headlines, and media speculation about China Pharma that are available to investors today. That information is available publicly through China media outlets and privately through word of mouth or via China internal channels. However, regardless of the origin, that massive amount of China data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of China Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of China Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to China Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive China Pharma alpha.
China Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards China Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between China Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.